Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Ticker SymbolSTTK
Company nameShattuck Labs Inc
IPO dateOct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
Number of employees44
Security typeOrdinary Share
Fiscal year-endOct 09
Address500 W. 5Th Street
CityAUSTIN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code78701
Phone15129004690
Websitehttps://www.shattucklabs.com/
Ticker SymbolSTTK
IPO dateOct 09, 2020
CEODr. Taylor Schreiber, M.D., Ph.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data